Overview


According to FutureWise analysis the market for liposome drug delivery in 2023 is US$ 5.11 billion, and is expected to reach US$ 9.97 billion by 2031 at a CAGR of 8.72%.

Liposomes are new drug delivery systems (NDDS) consisting of bilayers that form naturally when phospholipids are dispersed in water. Microscopic vesicles with aqueous volumes are completely enclosed by membranes composed of lipid bilayers. The liposome drug delivery market is capitalizing on this opportunity by investing in nanomaterials such as nanospheres, liposomes, and nanoparticles that have proven antiviral properties. With an increase in vivo and in vitro drug activities, liposomes are increasingly being used in clinical practice. In the liposome drug delivery market, companies are increasingly focused on the development of nanosystems for the delivery of antiviral drugs across cellular and intracellular barriers. Therefore, liposomes have promising potential in ongoing research studies being conducted by healthcare companies for the treatment of Coronavirus.

For pharmaceutical companies, new strategies for surface modification of liposomes are creating incremental opportunities. Several studies have demonstrated that liposome delivery is a useful tool for the vehicle action and delivery of lipophilic, hydrophilic, and amphiphilic compounds. There are however limitations faced by companies in the liposome drug delivery market because of high toxicity and resistance in high doses. Due to this, companies are moving away from simple conventional vesicles and into second-generation liposomes by adapting their lipid composition and surface with different ligands. In recent years, PEGylated liposomes have gained popularity due to their capacity to load more drugs. A novel drug encapsulated within liposomes such as the CPX-1 has been shown to improve disease control for patients suffering from colorectal cancer. Therefore, the revenue of the cancer therapy application segment is expected to grow aggressively over the forecast period.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Liposome Drug Delivery Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Liposome Drug Delivery Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Spectrum Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.
  • Gilead Sciences, Inc.
  • Celsion Corporation
  • Ipsen Pharma
  • Pacira BioSciences, Inc.
  • Luye Pharma Group
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Johnson and Johnson

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product

  • Liposomal Doxorubicin
  • Liposomal Paclitaxel
  • Liposomal Amphotericin B
  • Others

By Technology

  • Stealth Liposome Technology
  • Non-PEGylated Liposome Technology
  • DepoFoam Liposome Technology

By Application

  • Fungal Diseases
  • Cancer Therapy
  • Pain Management
  • Viral Vaccines
  • Photodynamic Therapy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Liposome Drug Delivery Market By Product, By Technology, By Application and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Liposome Drug Delivery Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Liposome Drug Delivery Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Liposome Drug Delivery Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Liposome Drug Delivery Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Liposomal Doxorubicin
        2. Liposomal Paclitaxel
        3. Liposomal Amphotericin B
        4. Others

  • 8.   Liposome Drug Delivery Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Stealth Liposome Technology
        2. Non-PEGylated Liposome Technology
        3. DepoFoam Liposome Technology

  • 9.   Liposome Drug Delivery Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Fungal Diseases
        2. Cancer Therapy
        3. Pain Management
        4. Viral Vaccines
        5. Photodynamic Therapy

  • 10.   North America Liposome Drug Delivery Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Liposome Drug Delivery Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Liposome Drug Delivery Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Liposome Drug Delivery Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Spectrum Pharmaceuticals, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Astellas Pharma, Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Gilead Sciences, Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Celsion Corporation
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Ipsen Pharma
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Pacira BioSciences, Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Luye Pharma Group
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Novartis AG
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Takeda Pharmaceutical Company Limited
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Johnson and Johnson
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients